



Clinical trial results:

A Phase 2, randomised, observer-blind, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' GSK3277511A investigational vaccine when administered intramuscularly according to two different vaccine schedules in adults aged 40 to 80 years old

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2017-002941-31 |
| Trial protocol | DE GB |
| Global end of trial date | |

Results information

| | |
|--------------------------------|-------------------|
| Result version number | v1 |
| This version publication date | 30 September 2020 |
| First version publication date | 30 September 2020 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 207759 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GlaxoSmithKline |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | GSK Response Center, GlaxoSmithKline, 044 2089-904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | GSK Response Center, GlaxoSmithKline, 044 2089-904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Interim |
| Date of interim/final analysis | 30 March 2020 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 31 December 2019 |
| Global end of trial reached? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and reactogenicity profile of the NTHi-Mcat vaccine administered according to two vaccination schedules

Protection of trial subjects:

All subjects were supervised for 60 min after vaccination with appropriate medical treatment available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccine.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 20 March 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Canada: 100 |
| Country: Number of subjects enrolled | Germany: 50 |
| Country: Number of subjects enrolled | United Kingdom: 50 |
| Worldwide total number of subjects | 200 |
| EEA total number of subjects | 100 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 133 |
| From 65 to 84 years | 67 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

All subjects enrolled were included for analysis in this study

Period 1

| | |
|----------------------------------|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst, Carer, Assessor |
| Blinding implementation details: | |
| This is an observer blind study. | |

Arms

| | |
|------------------------------|----------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Schedule 0-2-6 Group |

Arm description:

Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | NTHi Mcat investigational vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder and solvent for suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Three doses administered intramuscularly in the deltoid of the non-dominant arm

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

One dose administered intramuscularly in the deltoid of the non-dominant arm

| | |
|------------------|-----------------------|
| Arm title | Schedule 0-2-12 Group |
|------------------|-----------------------|

Arm description:

Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

One dose administered intramuscularly in the deltoid of the non-dominant arm

| | |
|--|---|
| Investigational medicinal product name | NTHi Mcat investigational vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder and solvent for suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Three doses administered intramuscularly in the deltoid of the non-dominant arm

| Number of subjects in period 1 | Schedule 0-2-6 Group | Schedule 0-2-12 Group |
|---|-------------------------|--------------------------|
| Started | 100 | 100 |
| Completed | 92 | 95 |
| Not completed | 8 | 5 |
| Adverse event, non-fatal | 2 | 3 |
| CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT | 6 | 2 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|----------------------|
| Reporting group title | Schedule 0-2-6 Group |
|-----------------------|----------------------|

Reporting group description:

Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).

| | |
|-----------------------|-----------------------|
| Reporting group title | Schedule 0-2-12 Group |
|-----------------------|-----------------------|

Reporting group description:

Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).

| Reporting group values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | Total |
|----------------------------------|----------------------|-----------------------|-------|
| Number of subjects | 100 | 100 | 200 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 68 | 65 | 133 |
| From 65-84 years | 32 | 35 | 67 |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 58.4 | 59.8 | |
| standard deviation | ± 10.3 | ± 10.1 | - |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| FEMALE | 46 | 43 | 89 |
| MALE | 54 | 57 | 111 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 1 | 1 |
| WHITE | 100 | 99 | 199 |

End points

End points reporting groups

| | |
|--|-----------------------|
| Reporting group title | Schedule 0-2-6 Group |
| Reporting group description: | |
| Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12). | |
| Reporting group title | Schedule 0-2-12 Group |
| Reporting group description: | |
| Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6). | |

Primary: Number of subjects reported with each solicited local adverse event (AE) (any and grade 3) within each vaccination schedule

| | |
|--|--|
| End point title | Number of subjects reported with each solicited local adverse event (AE) (any and grade 3) within each vaccination schedule ^[1] |
| End point description: | |
| Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) injection site. Analysis was performed on the Exposed set which included all eligible subjects, enrolled in this study, who provided informed consent, had at least one vaccine dose administered and who provided solicited safety data. | |
| End point type | Primary |
| End point timeframe: | |
| During the 7-day follow-up period (the day of vaccination + 6 days) after each vaccination administered at Day 1, Day 61, Day 181 and Day 361 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Scope of this endpoint analysis was descriptive. Therefore, no statistical analyses apply for this endpoint

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|--------------------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 100 | 100 | | |
| Units: Participants | | | | |
| Pain, Any, Dose 1 (N-100,100) | 64 | 64 | | |
| Pain, Grade 3, Dose 1 (N-100,100) | 2 | 1 | | |
| Pain, Any, Dose 2(N-92,97) | 72 | 69 | | |
| Pain, Grade 3, Dose 2(N-92,97) | 13 | 3 | | |
| Pain, Any, Dose 3(N-89,97) | 67 | 4 | | |
| Pain, Grade 3, Dose 3(N-89,97) | 12 | 0 | | |
| Pain, Any, Dose 4(N-84,93) | 9 | 73 | | |
| Pain, Grade 3, Dose 4(N-84,93) | 0 | 8 | | |
| Redness, Any, Dose 1 (N-100,100) | 9 | 18 | | |
| Redness, Grade 3, Dose 1 (N-100,100) | 0 | 0 | | |
| Redness, Any, Dose 2(N-92,97) | 12 | 11 | | |
| Redness, Grade 3, Dose 2(N-92,97) | 0 | 0 | | |
| Redness, Any, Dose 3(N-89,97) | 13 | 0 | | |

| | | | | |
|--------------------------------------|---|----|--|--|
| Redness, Grade 3, Dose 3(N-89,97) | 1 | 0 | | |
| Redness, Any, Dose 4(N-84,93) | 1 | 12 | | |
| Redness, Grade 3, Dose 4(N-84,93) | 0 | 1 | | |
| Swelling, Any, Dose 1(N-100,100) | 8 | 10 | | |
| Swelling, Grade 3, Dose 1(N-100,100) | 0 | 0 | | |
| Swelling, Any, Dose 2(N-92,97) | 7 | 7 | | |
| Swelling, Grade 3, Dose 2(N-92,97) | 0 | 0 | | |
| Swelling, Any, Dose 3(N-89,97) | 9 | 0 | | |
| Swelling, Grade 3, Dose 3(N-89,97) | 1 | 0 | | |
| Swelling, Any, Dose 4(N-84,93) | 1 | 10 | | |
| Swelling, Grade 3, Dose 4(N-84,93) | 0 | 1 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects reported with each solicited general adverse event (AE) (any and grade 3) within each vaccination schedule

| | |
|-----------------|--|
| End point title | Number of subjects reported with each solicited general adverse event (AE) (any and grade 3) within each vaccination schedule ^[2] |
|-----------------|--|

End point description:

Assessed solicited general symptoms were chills, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), fatigue, myalgia, headache and fever [defined Oral cavity or axillary temperature equal to or above (\geq) 37.5 degrees Celsius ($^{\circ}$ C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \geq 39.0 $^{\circ}$ C. Analysis was performed on the Exposed set which included all eligible subjects, enrolled in this study, who provided informed consent, had at least one vaccine dose administered and who provided solicited safety data.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the 7-day follow-up period (the day of vaccination + 6 days) after each vaccination administered at Day 1, Day 61, Day 181 and Day 361

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Scope of this endpoint analysis was descriptive. Therefore, no statistical analyses apply for this endpoint

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|------------------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 100 | 100 | | |
| Units: Participants | | | | |
| Chills, Any, Dose 1 (N-100,100) | 6 | 5 | | |
| Chills, Grade 3, Dose 1(N-100,100) | 0 | 0 | | |
| Chills, Any, Dose 2(N-92,97) | 13 | 8 | | |
| Chills, Grade 3, Dose 2(N-92,97) | 4 | 1 | | |
| Chills, Any, Dose 3(N-89,97) | 12 | 2 | | |
| Chills, Grade 3, Dose 3(N-89,97) | 4 | 0 | | |
| Chills, Any, Dose 4(N-84,93) | 2 | 18 | | |
| Chills, Grade 3, Dose 4(N-84,93) | 1 | 1 | | |

| | | | | |
|--|----|----|--|--|
| Gastrointestinal symptoms,Any,Dose 1(N-100,100) | 11 | 7 | | |
| Gastrointestinal symptoms,Grade3,Dose 1(N-100,100) | 0 | 0 | | |
| Gastrointestinal symptoms,Any,Dose 2(N-92,97) | 11 | 10 | | |
| Gastrointestinal symptoms,Grade3,Dose 2(N-92,97) | 1 | 1 | | |
| Gastrointestinal symptoms, Any, Dose 3(N-89,97) | 9 | 7 | | |
| Gastrointestinal symptoms,Grade3,Dose 3(N-89,97) | 0 | 0 | | |
| Gastrointestinal symptoms, Any,Dose 4(N-84,93) | 3 | 15 | | |
| Gastrointestinal symptoms,Grade3,Dose 4(N-84,93) | 1 | 1 | | |
| Fatigue, Any, Dose 1(N-100,100) | 22 | 16 | | |
| Fatigue, Grade 3, Dose 1(N-100,100) | 0 | 1 | | |
| Fatigue, Any, Dose 2(N-92,97) | 28 | 32 | | |
| Fatigue, Grade 3, Dose 2(N-92,97) | 9 | 1 | | |
| Fatigue, Any, Dose 3(N-89,97) | 20 | 13 | | |
| Fatigue, Grade 3, Dose 3(N-89,97) | 4 | 0 | | |
| Fatigue, Any, Dose 4(N-84,93) | 8 | 35 | | |
| Fatigue, Grade 3, Dose 4(N-84,93) | 3 | 5 | | |
| Myalgia, Any, Dose 1(N-100,100) | 17 | 16 | | |
| Myalgia, Grade 3, Dose 1(N-100,100) | 1 | 0 | | |
| Myalgia, Any, Dose 2(N-92,97) | 22 | 23 | | |
| Myalgia, Grade 3, Dose 2(N-92,97) | 7 | 1 | | |
| Myalgia, Any, Dose 3(N-89,97) | 20 | 3 | | |
| Myalgia, Grade 3, Dose 3(N-89,97) | 6 | 0 | | |
| Myalgia, Any, Dose 4(N-84,93) | 4 | 28 | | |
| Myalgia, Grade 3, Dose 4(N-84,93) | 1 | 5 | | |
| Headache, Any, Dose 1(N-100,100) | 13 | 15 | | |
| Headache, Grade 3, Dose 1(N-100,100) | 0 | 1 | | |
| Headache, Any, Dose 2(N-92,97) | 24 | 21 | | |
| Headache, Grade 3, Dose 2(N-92,97) | 2 | 1 | | |
| Headache, Any, Dose 3(N-89,97) | 24 | 7 | | |
| Headache, Grade 3, Dose 3(N-89,97) | 4 | 0 | | |
| Headache, Any, Dose 4(N-84,93) | 5 | 27 | | |
| Headache, Grade 3, Dose 4(N-84,93) | 1 | 1 | | |
| Fever, Any, Dose 1(N-100,100) | 3 | 3 | | |
| Fever, Grade 3, Dose 1(N-100,100) | 0 | 0 | | |
| Fever, Any, Dose 2(N-92,97) | 3 | 6 | | |
| Fever, Grade 3, Dose 2(N-92,97) | 0 | 0 | | |
| Fever, Any, Dose 3(N-89,97) | 4 | 2 | | |
| Fever, Grade 3, Dose 3(N-89,97) | 0 | 0 | | |
| Fever, Any, Dose 4(N-84,93) | 3 | 5 | | |
| Fever, Grade 3, Dose 4(N-84,93) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects reported with any unsolicited adverse event (AE) within each vaccination schedule

| | |
|-----------------|---|
| End point title | Number of subjects reported with any unsolicited adverse event (AE) within each vaccination schedule ^[3] |
|-----------------|---|

End point description:

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Analysis was performed on the Exposed set which included all eligible subjects, enrolled in this study, who provided informed consent, had at least one vaccine dose administered and who provided unsolicited safety data.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the 30-day follow-up period (the day of vaccination + 29 days) after each vaccination administered at Day 1, Day 61, Day 181 and Day 361

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Scope of this endpoint analysis was descriptive. Therefore, no statistical analyses apply for this endpoint

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 100 | 100 | | |
| Units: Participants | | | | |
| Dose 1 (N-100,100) | 16 | 20 | | |
| Dose 2 (N-93,98) | 15 | 20 | | |
| Dose 3 (N-90,97) | 13 | 11 | | |
| Dose 4 (N-85,93) | 7 | 9 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects reported with any serious adverse event (SAE) within each vaccination schedule

| | |
|-----------------|--|
| End point title | Number of subjects reported with any serious adverse event (SAE) within each vaccination schedule ^[4] |
|-----------------|--|

End point description:

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician. Analysis was performed on the Exposed set which included all eligible subjects, enrolled in this study, who provided informed consent, had at least one vaccine dose administered and who provided safety data.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From first vaccination (Day 1) up to Day 541 (an average of 18 months)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Scope of this endpoint analysis was descriptive. Therefore, no statistical analyses apply for this endpoint

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 100 | 100 | | |
| Units: Participants | 12 | 8 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects reported with any potential immune-mediated diseases (pIMDs) within each vaccination schedule

| | |
|-----------------|---|
| End point title | Number of subjects reported with any potential immune-mediated diseases (pIMDs) within each vaccination schedule ^[5] |
|-----------------|---|

End point description:

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Analysis was performed on the Exposed set which included all eligible subjects, enrolled in this study, who provided informed consent, had at least one vaccine dose administered and who provided safety data.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From first vaccination (Day 1) up to Day 541 (an average of 18 months)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Scope of this endpoint analysis was descriptive. Therefore, no statistical analyses apply for this endpoint

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 100 | 100 | | |
| Units: Participants | 3 | 3 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reported with any SAE within each vaccination schedule

| | |
|-----------------|---|
| End point title | Number of subjects reported with any SAE within each vaccination schedule |
|-----------------|---|

End point description:

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening,

required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician.

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| From Day 541 up to Day 721 (an average of 6 months) | |

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[6] | 0 ^[7] | | |
| Units: Participants | | | | |

Notes:

[6] - Data will be presented when results available

[7] - Data will be presented when results are available

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reported with any pIMDs within each vaccination schedule

| | |
|-----------------|---|
| End point title | Number of subjects reported with any pIMDs within each vaccination schedule |
|-----------------|---|

End point description:

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 541 up to Day 721 (an average of 6 months)

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[8] | 0 ^[9] | | |
| Units: Participants | | | | |

Notes:

[8] - Data will be presented when results are available

[9] - Data will be presented when results are available

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-Protein D (PD) antibody concentrations, as measured by ELISA, within each vaccination schedule

| | |
|-----------------|---|
| End point title | Anti-Protein D (PD) antibody concentrations, as measured by |
|-----------------|---|

End point description:

Anti-Protein D (PD) antibody concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), and expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EU/mL). Calculation of the GMCs are performed by taking the anti-logarithm in base 10 (anti-log₁₀) of the mean of the log₁₀ concentration transformations. Antibody concentrations below the assay cut-off (153 EU/mL) is given an arbitrary value of half the assay cut-off for the purpose of GMC calculation. Day 721 data analysis is not achieved at the time of the posting. Results will be added as soon as they are available. Analysis was performed on the Per Protocol Set population which included all eligible subjects enrolled in this study, who provided informed consent, who complied with the vaccination schedule and who provided immunogenicity data according to blood sample timings specified in the protocol

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, Day 361, Day 391, Day 541 and Day 721

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|--|---------------------------|---------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 82 | 87 | | |
| Units: EU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Day 1 (N-82,87) | 88 (79.2 to 97.9) | 88.1 (79.8 to 97.2) | | |
| Day 91(N-79,82) | 1365.5 (1073.0 to 1737.8) | 1394.1 (1116.9 to 1740.1) | | |
| Day 181(N-81,87) | 853.4 (665.4 to 1094.6) | 835.6 (665.4 to 1049.3) | | |
| Day 211(N-81,84) | 2338 (1840.1 to 2970.8) | 679 (541.7 to 850.9) | | |
| Day 361(N-82,87) | 1199 (942.8 to 1524.9) | 483.1 (386.4 to 603.9) | | |
| Day 391(N-81,82) | 1064.1 (829.4 to 1365.2) | 2677 (2111.4 to 3394.1) | | |
| Day 541(N-80,84) | 826.5 (646.3 to 1057.0) | 1346.4 (1072.1 to 1690.8) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-Protein E (PE) antibody concentrations, as measured by ELISA, within each vaccination schedule

| | |
|-----------------|---|
| End point title | Anti-Protein E (PE) antibody concentrations, as measured by ELISA, within each vaccination schedule |
|-----------------|---|

End point description:

Anti-Protein E (PE) antibody concentrations as determined by ELISA, and expressed in EU/mL. Calculation of the GMCs are performed by taking the anti-logarithm in base 10 (anti-log₁₀) of the mean of the log₁₀ concentration transformations. Antibody concentrations below the assay cut-off (16 EU/mL) is given an arbitrary value of half the assay cut-off for the purpose of GMC calculation. Day 721 data analysis is not achieved at the time of the posting. Results will be added as soon as they are available. Analysis was performed on the Per Protocol Set population which included all eligible subjects enrolled in

this study, who provided informed consent, who complied with the vaccination schedule and who provided immunogenicity data according to blood sample timings specified in the protocol

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, Day 361, Day 391, Day 541 and Day 721

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|--|---------------------------|----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 82 | 87 | | |
| Units: EU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Day 1 (N-82,87) | 19.6 (15.1 to 25.5) | 18.4 (14.5 to 23.5) | | |
| Day 91(N-79,82) | 5867.9 (4644.4 to 7413.8) | 5896.7 (4755.2 to 7312.3) | | |
| Day 181(N-81,87) | 2649.1 (2113.3 to 3320.7) | 2787.1 (2266.0 to 3428.0) | | |
| Day 211(N-80,84) | 7557.1 (6107.9 to 9350.0) | 2309.9 (1892.1 to 2819.8) | | |
| Day 361(N-82,87) | 2735.3 (2196.7 to 3406.1) | 1298 (1058.6 to 1591.6) | | |
| Day 391(N-81,82) | 2604.2 (2118.3 to 3201.5) | 9339.4 (7670.2 to 11372.0) | | |
| Day 541(N-80,84) | 1762.2 (1443.9 to 2150.6) | 3620.7 (3009.9 to 4355.4) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-type IV pili subunit (PiIA) antibody concentrations, as measured by ELISA, within each vaccination schedule

| | |
|-----------------|--|
| End point title | Anti-type IV pili subunit (PiIA) antibody concentrations, as measured by ELISA, within each vaccination schedule |
|-----------------|--|

End point description:

Anti-type IV pili subunit (PiIA) antibody concentrations as determined by ELISA, and expressed in EU/mL. Calculation of the GMCs are performed by taking the anti-logarithm in base 10 (anti-log₁₀) of the mean of the log₁₀ concentration transformations. Antibody concentrations below the assay cut-off (8 EU/mL) is given an arbitrary value of half the assay cut-off for the purpose of GMC calculation. Day 721 data analysis is not achieved at the time of the posting. Results will be added as soon as they are available. Analysis was performed on the Per Protocol Set population which included all eligible subjects enrolled in this study, who provided informed consent, who complied with the vaccination schedule and who provided immunogenicity data according to blood sample timings specified in the protocol

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, Day 361, Day 391, Day 541 and Day 721

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|--|--------------------------|--------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 82 | 87 | | |
| Units: EU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Day 1(N-82,87) | 10.9 (8.5 to 14.2) | 8.3 (6.5 to 10.5) | | |
| Day 91(N-79,82) | 992.5 (747.2 to 1318.5) | 893.1 (688.6 to 1158.3) | | |
| Day 181(N-81,87) | 589.3 (442.8 to 784.3) | 504.2 (388.4 to 654.3) | | |
| Day 211(N-81,84) | 1191.7 (920.0 to 1543.6) | 396.3 (310.9 to 505.2) | | |
| Day 361(N-82,87) | 546.6 (418.1 to 714.5) | 250.3 (195.3 to 320.7) | | |
| Day 391(N-81,82) | 456.4 (360.7 to 577.6) | 1163.9 (931.1 to 1454.9) | | |
| Day 541(N-80,84) | 330.4 (260.5 to 419.1) | 524.3 (421.0 to 653.1) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations, as measured by ELISA, within each vaccination schedule

| | |
|-----------------|---|
| End point title | Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations, as measured by ELISA, within each vaccination schedule |
|-----------------|---|

End point description:

Anti-ubiquitous surface protein A2 of Moraxella catarrhalis (UspA2) antibody concentrations as determined by ELISA, and expressed in EU/mL. Calculation of the GMCs are performed by taking the anti-logarithm in base 10 (anti-log10) of the mean of the log10 concentration transformations. Antibody concentrations below the assay cut-off (28 EU/mL) is given an arbitrary value of half the assay cut-off for the purpose of GMC calculation. Day 721 data analysis is not achieved at the time of the posting. Results will be added as soon as they are available. Analysis was performed on the Per Protocol Set population which included all eligible subjects enrolled in this study, who provided informed consent, who complied with the vaccination schedule and who provided immunogenicity data according to blood sample timings specified in the protocol

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, Day 361, Day 391, Day 541 and Day 721

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|--|---------------------------|---------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 82 | 87 | | |
| Units: EU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Day 1(N-82,87) | 682.4 (544.4 to 855.4) | 544.9 (441.8 to 672.1) | | |
| Day 91(N-79,82) | 1364.5 (1217.6 to 1529.1) | 1159.7 (1044.8 to 1287.2) | | |
| Day 181(N-81,87) | 1019.7 (920.9 to 1129.0) | 915.2 (834.1 to 1004.3) | | |
| Day 211(N-81,84) | 1270.9 (1138.1 to 1419.2) | 864.6 (779.5 to 959.1) | | |
| Day 361(N-82,87) | 885.8 (801.7 to 978.8) | 730 (665.6 to 800.6) | | |
| Day 391(N-81,82) | 909.9 (818.5 to 1011.4) | 1142.8 (1033.9 to 1263.3) | | |
| Day 541(N-80,84) | 898.2 (811.5 to 994.2) | 847.4 (771.6 to 930.7) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti-PD antibody, as measured by ELISA, within each vaccination schedule

| | |
|-----------------|--|
| End point title | Number of seropositive subjects for anti-PD antibody, as measured by ELISA, within each vaccination schedule |
|-----------------|--|

End point description:

A Seropositive subject is defined as a subject whose antibody concentration is greater than or equal to the assay cut off (i.e. the ELISA lower limit of quantification = 153 EU/mL). Antibody concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), and expressed in EU/mL. Day 721 data analysis is not achieved at the time of the posting. Results will be added as soon as they are available. Analysis was performed on the Per Protocol Set population which included all eligible subjects enrolled in this study, who provided informed consent, who complied with the vaccination schedule and who provided immunogenicity data according to blood sample timings specified in the protocol

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, Day 361, Day 391, Day 541 and Day 721

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 82 | 87 | | |
| Units: Participants | | | | |
| Day 1(N-82,87) | 7 | 12 | | |
| Day 91(N-79,82) | 78 | 80 | | |
| Day 181(N-81,87) | 75 | 80 | | |

| | | | | |
|------------------|----|----|--|--|
| Day 211(N-81,84) | 81 | 75 | | |
| Day 361(N-82,87) | 78 | 71 | | |
| Day 391(N-81,82) | 77 | 81 | | |
| Day 541(N-80,84) | 76 | 79 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti-PE antibody, as measured by ELISA, within each vaccination schedule

| | |
|-----------------|--|
| End point title | Number of seropositive subjects for anti-PE antibody, as measured by ELISA, within each vaccination schedule |
|-----------------|--|

End point description:

A Seropositive subject is defined as a subject whose antibody concentration is greater than or equal to the assay cut off (i.e. the ELISA lower limit of quantification = 16 EU/mL). Antibody concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), and expressed in EU/mL. Day 721 data analysis is not achieved at the time of the posting. Results will be added as soon as they are available. Analysis was performed on the Per Protocol Set population which included all eligible subjects enrolled in this study, who provided informed consent, who complied with the vaccination schedule and who provided immunogenicity data according to blood sample timings specified in the protocol

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, Day 361, Day 391, Day 541 and Day 721

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 82 | 87 | | |
| Units: Participants | | | | |
| Day 1(N-82,87) | 43 | 43 | | |
| Day 91(N-79,82) | 79 | 82 | | |
| Day 181(N-81,87) | 81 | 87 | | |
| Day 211(N-80,84) | 80 | 84 | | |
| Day 361(N-82,87) | 82 | 87 | | |
| Day 391(N-81,82) | 81 | 82 | | |
| Day 541(N-80,84) | 80 | 84 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti- PiIA antibody, as measured by ELISA, within each vaccination schedule

| | |
|-----------------|---|
| End point title | Number of seropositive subjects for anti- PiIA antibody, as measured by ELISA, within each vaccination schedule |
|-----------------|---|

End point description:

A Seropositive subject is defined as a subject whose antibody concentration is greater than or equal to the assay cut off (i.e. the ELISA lower limit of quantification = 8 EU/mL). Antibody concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), and expressed in EU/mL. Day 721 data analysis is not achieved at the time of the posting. Results will be added as soon as they are available. Analysis was performed on the Per Protocol Set population which included all eligible subjects enrolled in this study, who provided informed consent, who complied with the vaccination schedule and who provided immunogenicity data according to blood sample timings specified in the protocol

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, Day 361, Day 391, Day 541 and Day 721

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 82 | 87 | | |
| Units: Participants | | | | |
| Day 1(N-82,87) | 40 | 36 | | |
| Day 91(N-79,82) | 79 | 82 | | |
| Day 181(N-81,87) | 81 | 87 | | |
| Day 211(N-81,84) | 81 | 83 | | |
| Day 361(N-82,87) | 82 | 84 | | |
| Day 391(N-81,82) | 81 | 82 | | |
| Day 541(N-80,84) | 80 | 84 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti- UspA2 antibody, as measured by ELISA, within each vaccination schedule

| | |
|-----------------|--|
| End point title | Number of seropositive subjects for anti- UspA2 antibody, as measured by ELISA, within each vaccination schedule |
|-----------------|--|

End point description:

A Seropositive subject is defined as a subject whose antibody concentration is greater than or equal to the assay cut off (i.e. the ELISA lower limit of quantification = 28 EU/mL). Antibody concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), and expressed in EU/mL. Day 721 data analysis is not achieved at the time of the posting. Results will be added as soon as they are available. Analysis was performed on the Per Protocol Set population which included all eligible subjects enrolled in this study, who provided informed consent, who complied with the vaccination schedule and who provided immunogenicity data according to blood sample timings specified in the protocol

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, Day 361, Day 391, Day 541 and Day 721

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|-----------------------------|----------------------|-----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 82 | 87 | | |
| Units: Participants | | | | |
| Day 1(N-82,87) | 82 | 87 | | |
| Day 91(N-79,82) | 79 | 82 | | |
| Day 181(N-81,87) | 81 | 87 | | |
| Day 211(N-81,84) | 81 | 84 | | |
| Day 361(N-82,87) | 82 | 87 | | |
| Day 391(N-81,82) | 81 | 82 | | |
| Day 541(N-80,84) | 80 | 84 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Frequency of Specific Cluster of Differentiation 4 (CD4+) T-cells producing 2 or more markers upon in vitro stimulation with the antigen, by NTHi Antigen

| | |
|-----------------|---|
| End point title | Frequency of Specific Cluster of Differentiation 4 (CD4+) T-cells producing 2 or more markers upon in vitro stimulation with the antigen, by NTHi Antigen |
|-----------------|---|

End point description:

Frequency of specific CD4+ T-cells were measured by flow cytometry intracellular cytokine staining (ICS) expressing two or more markers [such as Interleukin-2 (IL-2), IL-13, IL-17, Interferon- γ (IFN- γ), Tumor Necrosis Factor- α (TNF- α) and Cluster of Differentiation 40 Ligand (CD40L)]. The frequency of specific CD4+ T-cells are summarized with following descriptive statistics: Mean and standard deviation (SD) against each antigen (PD, PE, PiA and UspA2), by group and at each time point for which blood samples were collected for Cell-Mediated Immunity (CMI). The CMI sub-cohort subjects were selected from sites able to process the blood samples according to GSK procedures for peripheral blood mononuclear cell (PBMC) preparation. Analysis was performed on a subset of subjects (CMI sub cohort), which included approximately 20 subjects in each group, for which additional blood sample was taken at each pre-defined timepoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, Day 91, Day 181, Day 211, day 361 and Day 391

| End point values | Schedule 0-2-6 Group | Schedule 0-2-12 Group | | |
|--------------------------------------|--------------------------|---------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 21 | 19 | | |
| Units: CD4+ T-cells/million cells | | | | |
| arithmetic mean (standard deviation) | | | | |
| NTHi.PD, Day 1(N-21,19) | 76.995 (\pm 142.760) | 55.173 (\pm 109.539) | | |
| NTHi.PD, Day 91(N-19,19) | 865.933 (\pm 919.585) | 1076.136 (\pm 970.670) | | |
| NTHi.PD, Day 181(N-17,19) | 381.265 (\pm 356.496) | 463.939 (\pm 558.441) | | |
| NTHi.PD, Day 211(N-17,19) | 664.044 (\pm 610.930) | 518.104 (\pm 513.462) | | |

| | | | | |
|---------------------------------------|-----------------------|---------------------|--|--|
| NTHi.PD, Day 361(N-17,17) | 444.129 (± 520.204) | 378.78 (± 456.970) | | |
| NTHi.PD, Day 391(N-17,17) | 321.28 (± 316.073) | 761.605 (± 974.791) | | |
| NTHi.PE, Day 1(N-21,19) | 28.869 (± 44.944) | 21.223 (± 38.682) | | |
| NTHi.PE, Day 91(N-19,19) | 1406.663 (± 1900.558) | 926.809 (± 785.046) | | |
| NTHi.PE, Day 181(N-17,19) | 551.444 (± 635.058) | 352.471 (± 403.081) | | |
| NTHi.PE, Day 211(N-17,19) | 986.138 (± 1570.491) | 463.076 (± 395.158) | | |
| NTHi.PE, Day 361(N-17,17) | 636.539 (± 995.486) | 305.772 (± 337.400) | | |
| NTHi.PE, Day 391(N-17,17) | 590.426 (± 714.051) | 481.133 (± 533.658) | | |
| NTHi.PiIA, Day 1(N-21,19) | 81.03 (± 178.861) | 79.205 (± 210.642) | | |
| NTHi.PiIA, Day 91(N-19,19) | 615.698 (± 686.114) | 523.195 (± 493.956) | | |
| NTHi.PiIA, Day 181(N-17,19) | 356.275 (± 350.909) | 265.097 (± 267.351) | | |
| NTHi.PiIA, Day 211(N-17,19) | 524.754 (± 654.443) | 257.806 (± 252.382) | | |
| NTHi.PiIA, Day 361(N-17,17) | 341.58 (± 433.970) | 205.388 (± 220.979) | | |
| NTHi.PiIA, Day 391(N-17,17) | 334.088 (± 300.114) | 368.693 (± 354.449) | | |
| M catarrhalis.UspA2,Day 1(N-21,19) | 85.785 (± 99.051) | 53.391 (± 80.742) | | |
| M catarrhalis.UspA2, Day 91(N-19,19) | 964.521 (± 709.134) | 730.725 (± 575.778) | | |
| M catarrhalis.UspA2, Day 181(N-17,19) | 559.062 (± 524.096) | 355.992 (± 346.277) | | |
| M catarrhalis.UspA2, Day 211(N-17,19) | 846.177 (± 750.349) | 424.981 (± 329.334) | | |
| M catarrhalis.UspA2, Day 361(N-17,17) | 635.022 (± 617.485) | 347.65 (± 363.499) | | |
| M catarrhalis.UspA2, Day 391(N-17,17) | 545.436 (± 464.272) | 474.238 (± 446.236) | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited AEs were collected during the 7-day follow-up period after any vaccination, Unsolicited AEs during the 30-day follow-up period after any vaccination, and SAEs from Day 1 to Day 541.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 22.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-----------------------|
| Reporting group title | Schedule 0-2-12 Group |
|-----------------------|-----------------------|

Reporting group description:

Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).

| | |
|-----------------------|----------------------|
| Reporting group title | Schedule 0-2-6 Group |
|-----------------------|----------------------|

Reporting group description:

Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).

| Serious adverse events | Schedule 0-2-12 Group | Schedule 0-2-6 Group | |
|---|-----------------------|----------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 8 / 100 (8.00%) | 12 / 100 (12.00%) | |
| number of deaths (all causes) | 2 | 1 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Invasive lobular breast carcinoma | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung cancer metastatic | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|--|-----------------|-----------------|--|
| Lung neoplasm malignant subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Chest injury | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Head injury | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tendon rupture | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tooth injury | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute myocardial infarction | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Right ventricular failure | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Cerebral artery occlusion | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Death | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |

| | | | |
|---|-----------------|-----------------|--|
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Pain of skin | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Conversion disorder | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulitis | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 100 (1.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Schedule 0-2-12 Group | Schedule 0-2-6 Group | |
|---|--------------------------|-------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 97 / 100 (97.00%) | 93 / 100 (93.00%) | |
| Vascular disorders | | | |
| Hot flush | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 1 | 1 | |
| Hypertension | | | |
| subjects affected / exposed | 4 / 100 (4.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 4 | 0 | |
| General disorders and administration site conditions | | | |
| Administration site pruritus | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Chest pain | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 1 | 1 | |
| Chills | | | |
| subjects affected / exposed | 25 / 100 (25.00%) | 24 / 100 (24.00%) | |
| occurrences (all) | 34 | 33 | |
| Fatigue | | | |

| | | | |
|-----------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 50 / 100 (50.00%) | 44 / 100 (44.00%) | |
| occurrences (all) | 97 | 79 | |
| Feeling hot | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Influenza like illness | | | |
| subjects affected / exposed | 2 / 100 (2.00%) | 2 / 100 (2.00%) | |
| occurrences (all) | 2 | 2 | |
| Injection site erythema | | | |
| subjects affected / exposed | 28 / 100 (28.00%) | 21 / 100 (21.00%) | |
| occurrences (all) | 41 | 35 | |
| Injection site pain | | | |
| subjects affected / exposed | 92 / 100 (92.00%) | 89 / 100 (89.00%) | |
| occurrences (all) | 210 | 213 | |
| Injection site pruritus | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Injection site swelling | | | |
| subjects affected / exposed | 20 / 100 (20.00%) | 16 / 100 (16.00%) | |
| occurrences (all) | 27 | 25 | |
| Malaise | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 1 | 1 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Peripheral swelling | | | |
| subjects affected / exposed | 2 / 100 (2.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 13 / 100 (13.00%) | 11 / 100 (11.00%) | |
| occurrences (all) | 16 | 13 | |
| Immune system disorders | | | |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|---|-----------------|-----------------|--|
| Reproductive system and breast disorders | | | |
| Testicular pain | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 2 / 100 (2.00%) | |
| occurrences (all) | 1 | 2 | |
| Nasal congestion | | | |
| subjects affected / exposed | 3 / 100 (3.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 3 | 1 | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 2 | |
| Rhinitis allergic | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Wheezing | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 2 / 100 (2.00%) | |
| occurrences (all) | 0 | 2 | |
| Hallucination | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Stress | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|--|-------------------|-------------------|--|
| Investigations | | | |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Weight increased | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Injury, poisoning and procedural complications | | | |
| Concussion | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Contusion | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 2 / 100 (2.00%) | 2 / 100 (2.00%) | |
| occurrences (all) | 2 | 2 | |
| Headache | | | |
| subjects affected / exposed | 41 / 100 (41.00%) | 39 / 100 (39.00%) | |
| occurrences (all) | 71 | 69 | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Migraine | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nerve compression | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Presyncope | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |

| | | | |
|---|----------------------|----------------------|--|
| Sciatica subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Tremor subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Blood and lymphatic system disorders Iron deficiency anaemia subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 1 | |
| Lymphadenopathy subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Ear and labyrinth disorders Ear discomfort subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 1 | |
| Ear pain subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 2 | |
| Vertigo subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 1 | |
| Eye disorders Cataract subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 1 | |
| Dry eye subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Vision blurred subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 1 / 100 (1.00%) 1 | |

| | | |
|-----------------------------|-------------------|-------------------|
| Abdominal pain | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 1 | 0 |
| Abdominal pain upper | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) |
| occurrences (all) | 0 | 1 |
| Diarrhoea | | |
| subjects affected / exposed | 3 / 100 (3.00%) | 1 / 100 (1.00%) |
| occurrences (all) | 3 | 1 |
| Dry mouth | | |
| subjects affected / exposed | 2 / 100 (2.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 2 | 0 |
| Dyspepsia | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) |
| occurrences (all) | 0 | 1 |
| Food poisoning | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastrointestinal disorder | | |
| subjects affected / exposed | 28 / 100 (28.00%) | 25 / 100 (25.00%) |
| occurrences (all) | 40 | 34 |
| Haemorrhoidal haemorrhage | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 1 | 0 |
| Haemorrhoids | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 1 | 0 |
| Large intestine polyp | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 1 | 0 |
| Nausea | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rectal haemorrhage | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) |
| occurrences (all) | 1 | 0 |

| | | | |
|---|----------------------|----------------------|--|
| Toothache subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Vomiting subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 1 | |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Erythema subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 1 | |
| Hyperhidrosis subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Night sweats subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Pruritus subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 1 | |
| Psoriasis subjects affected / exposed occurrences (all) | 0 / 100 (0.00%) 0 | 1 / 100 (1.00%) 2 | |
| Rash subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 1 | 0 / 100 (0.00%) 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthritis subjects affected / exposed occurrences (all) | 1 / 100 (1.00%) 2 | 0 / 100 (0.00%) 0 | |
| Back pain subjects affected / exposed occurrences (all) | 4 / 100 (4.00%) 4 | 2 / 100 (2.00%) 2 | |
| Joint swelling | | | |

| | | | |
|-----------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 2 / 100 (2.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 2 | 1 | |
| Myalgia | | | |
| subjects affected / exposed | 41 / 100 (41.00%) | 38 / 100 (38.00%) | |
| occurrences (all) | 73 | 63 | |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Synovial cyst | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Infections and infestations | | | |
| Alveolar osteitis | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 2 | |
| Eye infection | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Gingival abscess | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Infected bite | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |

| | | | |
|---|-----------------|-----------------|--|
| Localised infection | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 6 / 100 (6.00%) | 6 / 100 (6.00%) | |
| occurrences (all) | 6 | 6 | |
| Ophthalmic herpes simplex | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Sinusitis | | | |
| subjects affected / exposed | 2 / 100 (2.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 2 | 1 | |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 3 / 100 (3.00%) | |
| occurrences (all) | 0 | 3 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Vaginal infection | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |

| | | | |
|--------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 100 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Gout | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 100 (1.00%) | |
| occurrences (all) | 0 | 1 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|--------------|--|
| 24 July 2018 | MedDRA list for pIMDs updated with addition of gout as musculoskeletal disorder of interest |
| 24 July 2019 | ELISA cut off levels for humoral antibody response updated. CMI testing for CD8+ T cells measurement moved from secondary endpoints to tertiary endpoints. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported